Go Pro

Comera Life Sciences (CMRAW) 10K Form and Latest SEC Filings 2026

Latest Comera Life Sciences SEC Filings & Recent Activity

Comera Life Sciences (NASDAQ:CMRAW) has submitted 200+ documents to the U.S. Securities and Exchange Commission (SEC) since 2022. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form EFFECT submitted on February 27, 2024.

DateFilerForm TypeView
02/27/2024 11:15 PM
Comera Life Sciences (1907685) Filer
Form EFFECT
02/27/2024 11:15 PM
Comera Life Sciences (1907685) Filer
Form EFFECT
02/27/2024 11:15 PM
Comera Life Sciences (1907685) Filer
Form EFFECT
02/27/2024 11:15 PM
Comera Life Sciences (1907685) Filer
Form EFFECT
02/26/2024 3:31 PM
Comera Life Sciences (1907685) Filer
Form POS AM
02/26/2024 3:32 PM
Comera Life Sciences (1907685) Filer
Form POS AM
02/26/2024 3:33 PM
Comera Life Sciences (1907685) Filer
Form POS AM
02/26/2024 3:34 PM
Comera Life Sciences (1907685) Filer
Form POS AM
02/26/2024 3:35 PM
Comera Life Sciences (1907685) Filer
Form S-8 POS
02/26/2024 3:36 PM
Comera Life Sciences (1907685) Filer
Form S-8 POS
02/26/2024 3:37 PM
Comera Life Sciences (1907685) Filer
Form S-8 POS
02/15/2024 7:53 AM
Comera Life Sciences (1907685) Subject
Nasdaq Stock Market LLC (1354457) Filed by
Form 25-NSE
02/02/2024 6:48 PM
Comera Life Sciences (1907685) Issuer
Konar Shameek (1465302) Reporting
Konar Victoria (2010586) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2024 6:47 PM
Comera Life Sciences (1907685) Issuer
Konar Shameek (1465302) Reporting
Konar Victoria (2010586) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/30/2024 4:00 PM
Comera Life Sciences (1907685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/30/2024 4:02 PM
Comera Life Sciences (1907685) Filer
Form 424B3
01/30/2024 4:03 PM
Comera Life Sciences (1907685) Filer
Form 424B3
01/30/2024 4:04 PM
Comera Life Sciences (1907685) Filer
Form 424B3
01/11/2024 6:11 PM
Comera Life Sciences (1907685) Issuer
DENNY GEORGE P III (1234956) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/11/2024 6:14 PM
Comera Life Sciences (1907685) Issuer
DENNY GEORGE P III (1234956) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2024 4:33 PM
Comera Life Sciences (1907685) Issuer
HALPERN JOHN D (1234950) Reporting
Halpern Katherine H. (1862932) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2024 4:30 PM
Comera Life Sciences (1907685) Issuer
Warren Street Legacy, LLC (2007288) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/08/2024 4:30 PM
Comera Life Sciences (1907685) Issuer
Halpern Tucker R. (2007323) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/05/2024 6:30 PM
Comera Life Sciences (1907685) Filer
Form D
Notice of Exempt Offering of Securities 
01/05/2024 4:58 PM
Comera Life Sciences (1907685) Issuer
IAF, LLC (1989492) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/05/2024 4:59 PM
Comera Life Sciences (1907685) Issuer
IAF, LLC (1989492) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2024 7:38 PM
Cherington Charles (1448698) Reporting
Comera Life Sciences (1907685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2024 7:09 PM
Comera Life Sciences (1907685) Issuer
Freebird Investments LLC (1971406) Reporting
Freebird Partners LP (1955231) Reporting
HUFF CURTIS W (1250127) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2024 6:40 PM
Comera Life Sciences (1907685) Issuer
Freebird Investments LLC (1971406) Reporting
Freebird Partners LP (1955231) Reporting
HUFF CURTIS W (1250127) Reporting
Form 3
Initial statement of beneficial ownership of securities  
01/03/2024 5:30 PM
Comera Life Sciences (1907685) Issuer
Soane David (1948079) Reporting
Soane Family Trust (1952504) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023 4:17 PM
Comera Life Sciences (1907685) Filer
Form 424B3
12/29/2023 4:17 PM
Comera Life Sciences (1907685) Filer
Form 424B3
12/29/2023 4:20 PM
Comera Life Sciences (1907685) Filer
Form 424B3
12/29/2023 4:20 PM
Comera Life Sciences (1907685) Filer
Form 424B3
12/29/2023 4:00 PM
Comera Life Sciences (1907685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/29/2023 4:15 PM
Comera Life Sciences (1907685) Filer
Form 424B3
12/06/2023 7:30 AM
Comera Life Sciences (1907685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/06/2023 7:32 AM
Comera Life Sciences (1907685) Filer
Form 424B3
12/06/2023 7:34 AM
Comera Life Sciences (1907685) Filer
Form 424B3
12/06/2023 7:37 AM
Comera Life Sciences (1907685) Filer
Form 424B3
11/28/2023 3:25 PM
Campbell Michael Gerard (1934174) Reporting
Comera Life Sciences (1907685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
The $15 Gold Fund That Pays Up to $1,152/Month (Ad)

Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel

Discover the gold income fund before the next payout date
11/16/2023 3:32 PM
Comera Life Sciences (1907685) Filer
Form 424B3
11/16/2023 3:33 PM
Comera Life Sciences (1907685) Filer
Form 424B3
11/16/2023 3:34 PM
Comera Life Sciences (1907685) Filer
Form 424B3
11/16/2023 3:30 PM
Comera Life Sciences (1907685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2023 3:31 PM
Banerjee Sirshendu Roopom (1926535) Reporting
Comera Life Sciences (1907685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2023 3:32 PM
Comera Life Sciences (1907685) Issuer
Sullivan Edward Aloysius Jr. (1929093) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2023 5:30 AM
Clarke Dorothy J (1992152) Reporting
Comera Life Sciences (1907685) Issuer
Form 3
Initial statement of beneficial ownership of securities  
11/13/2023 5:31 AM
Clarke Dorothy J (1992152) Reporting
Comera Life Sciences (1907685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2023 3:59 PM
Comera Life Sciences (1907685) Issuer
McCourt Janice (1953540) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2023 4:02 PM
Comera Life Sciences (1907685) Issuer
Muni Neal (1926228) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/06/2023 3:30 PM
Comera Life Sciences (1907685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/02/2023 3:31 PM
Comera Life Sciences (1907685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/13/2023 11:15 PM
Comera Life Sciences (1907685) Filer
Form EFFECT
09/13/2023 3:30 PM
Comera Life Sciences (1907685) Filer
Form 424B3
09/13/2023 3:30 PM
Comera Life Sciences (1907685) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/12/2023 3:52 PM
Comera Life Sciences (1907685) Issuer
Soane David (1948079) Reporting
Soane Family Trust (1952504) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/11/2023 7:24 PM
Cherington Charles (1448698) Reporting
Comera Life Sciences (1907685) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/07/2023 7:05 PM
Cherington Charles (1448698) Filed by
Comera Life Sciences (1907685) Subject
Form SC 13D/A
(Data available from 1/1/2016 forward)

Comera Life Sciences SEC Filings - Frequently Asked Questions

Comera Life Sciences (CMRAW) has submitted 200+ filings to the SEC since 2022. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form EFFECT submitted on February 27, 2024. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:CMRAW are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 2/27/2024. New filings are added as they're published.
From Our Partners